Design, Optimization, and Justification of RP-HPLC process for the Resolvation of Azelnidipine in bulk plus in Pharmaceutical Components-Reference-Cited by-同舟云学术

Design, Optimization, and Justification of RP-HPLC process for the Resolvation of Azelnidipine in bulk plus in Pharmaceutical Components

Published:2024-05-15 Issue: Volume: Page:2175-2179
ISSN:0974-360X
Container-title:Research Journal of Pharmacy and Technology
language:en
Short-container-title:RJPT

Author:

Latha M.¹,Annam Sri Charitha²,Bhavani M. Durga³,Kumar G. Ravi⁴,Rao M. Subba⁵

Affiliation:

1. Dept. of Basic Science and Humanities, Dhanekula Institute of Engineering and Technology, Ganguru, Vijayawada - 521139, AP, India.

2. Department of Humanities and Sciences, VNR Vignana Jyothi Institute of Engineering and Technology, Hyderabad. 500090, Telangana, India.

3. Dept. of Chemistry, V.R. Siddhartha Engineering College, Kanuru, Vijayawada - 520 007, AP, India.

4. Department of Chemistry, Govt. Degree College, Siddipet - 502103, Telangana (Dt), India.

5. Dept. of Chemistry, University College of Sciences, Acharya Nagarjuna University, Guntur - 522510, AP, India.

Abstract

As part of this study, a new sensitive, convenient, accurate and robust reversed-phase high-performance liquid chromatography (RP-HPLC) method for the determination of azelidipine in pharmaceutical and tablet formulations was developed and validated. The three variables chosen were methanol concentration, flow rate, and pH in the mobile phase. Separation was performed using an HPLC method with a UV detector and a Chromosil C18 (250mm x 450mm). Methanol was pumped at a flow rate of 1.0mL/min and adjusted to pH 4.0 with dilute OPA (60:40% v/v) and pH 4.0 with potassium dihydrogen phosphate buffer (pH 4.0), 255nm.

Publisher

A and V Publications

Reference20 articles.

1. Chen BL. Zhang YZ. Luo JQ. Zhang W. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015; 11:309-18.

2. Shewale VU, Azelnidipine: A Review on Therapeutic Role in Hypertension. Journal of Drug Delivery and Therapeutics. 2019; 9: 1002-1005.

3. Noriaki Ikemura. Satoshi Yamaori. Chinatsu Kobayashi. Shinobu Kamijo. Norie Murayama. Hiroshi Yamazaki. Shigeru Ohmori. Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chemico-Biological Interactions. 2019; 306:1-9

4. Anil Kumar Meher. Anandan P. Arindam Mukhopadhyay. Estimation of Isradipine in Human Plasma by LCMS/MS. Asian J. Research Chem. 2011; 4(5):750-753.

5. Matsui T. Yamagishi S. Nakamura K. Inoue H. Azelnidipine. a new long-acting calcium-channel blocker. inhibits tumour necrosis factor-alpha-induced monocyte chemoattractant protein-1 expression in endothelial cells. J Int Med Res. 2006;34(6):671-675.